- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
45 Under 45: The Judges
Judges for the 2008 45 Under 45
To judge the Emerging Leadership Awards, Pharm Exec called on its Editorial Advisory Board members as well as other trusted sources. A comprehensive listing of those judges is included below:
Jeffrey Aronin, Ovation Pharmaceuticals
David Balekdjian, The Bruckner Group
Stan Bernard, MD, Bernard Associates
Steve Bliss, Innovex
Kevin Butler, Heritage Partners
Gary Cupit, Somnus Therapeutics
Todd Davis, Cowen Healthcare Royalty Partners
Craig Dunkley, Campbell Alliance
Rob Dhoble, DAS Healthcare, Omnicom
Sander Flaum, Flaum Partners
Cliff Kalb, C.Kalb & Associates, LLC
Mike Luby, TargetRx
Wayne Pines, APCO Worldwide
Peter Pitts, Center for Medicines in the Public Interest; Manning, Selvage & Lee
Douglas Plotkin, PA Consulting
Charlene Prounis, Flashpoint Medica
Mason Tenaglia, Amundsen Group
Alex Scott, Eisai
David Snow, AstraZeneca
Catherine Sohn, GlaxoSmithKline
Steve Rauschkolb, The Crisfield Group
Charlotte Sibley, Shire Pharmaceuticals
David Stern, EMD Serono
Bill Trombetta, St. Joseph’s University
Ceci Zak, Roche
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
